Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $43.45 up 0.39% from its previous closing price of $43.28. In other words, the price has increased by $0.39 from its previous closing price. On the day, 1.16 million shares were traded. CYTK stock price reached its highest trading level at $43.82 during the session, while it also had its lowest trading level at $42.705.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on February 07, 2025, initiated with a Buy rating and assigned the stock a target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.
On November 08, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $80.RBC Capital Mkts initiated its Outperform rating on November 08, 2024, with a $80 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 18 ’25 when Malik Fady Ibraham sold 2,000 shares for $43.58 per share. The transaction valued at 87,160 led to the insider holds 140,455 shares of the business.
Callos Andrew sold 2,775 shares of CYTK for $123,154 on Mar 17 ’25. The EVP, Chief Commercial Officer now owns 34,888 shares after completing the transaction at $44.38 per share. On Mar 17 ’25, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 4,389 shares for $44.38 each. As a result, the insider received 194,784 and left with 101,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5144957952 and an Enterprise Value of 4992111616. For the stock, the TTM Price-to-Sale (P/S) ratio is 278.56. Its current Enterprise Value per Revenue stands at 270.224 whereas that against EBITDA is -9.478.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.90, which has changed by -0.3419658 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $75.71, while it has fallen to a 52-week low of $40.53. The 50-Day Moving Average of the stock is -5.93%, while the 200-Day Moving Average is calculated to be -16.04%.
Shares Statistics:
For the past three months, CYTK has traded an average of 1.54M shares per day and 1437980 over the past ten days. A total of 118.21M shares are outstanding, with a floating share count of 115.45M. Insiders hold about 2.50% of the company’s shares, while institutions hold 109.76% stake in the company. Shares short for CYTK as of 1740700800 were 14072458 with a Short Ratio of 9.16, compared to 1738281600 on 13653135. Therefore, it implies a Short% of Shares Outstanding of 14072458 and a Short% of Float of 18.100001.
